Explore the leading data orchestration platforms for 2026 with quick comparisons, practical selection tips, and implementation guidance to keep your data pipelines reliable and scalable.
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen ...
Research reveals that LeapLogic delivers significantly higher conversion accuracy, faster transformation and time ...
UBS upgraded Palantir to Buy from Neutral, arguing the recent share price pullback has created a very compelling entry point for investors. Shares in the U.S. tech giant are currently trading 35% off ...
At the time of writing on Friday, the Palantir stock was down around 0.6%. On a year-to-date basis, the stock is down around 20%. The broader market was under pressure, with the Dow Jones Industrial ...
His Highness welcomed MGX’s timely rise as a leading global investor accelerating AI innovation and adoption to power a more prosperous future ...
The potential transaction is being explored to augment Tevogen’s existing capabilities and would result in Tevogen becoming a revenue-generating healthcare enterprise. Tevogen is evaluating the ...
Palantir Technologies (PLTR) was upgraded by UBS after shares of the enterprise software company fell by roughly 35% from its peak. Shares of Palantir rose 1.4% in extended trading on Thursday. “We ...
As OpenAI raises its megaround, Anthropic's battles multiply, and the SaaSpocalypse widens - but Dell cashes in - ...
Microsoft: A Very Healthy Business And Fairly Negative Sentiments: The Ingredients For A Timely Investment! Microsoft (MSFT) ...
The intersection of artificial intelligence and mechanistic neuroscience is rapidly transforming our understanding of neural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results